UPDATE: FDA approves first generic version of Suboxone sublingual film
Shares of London-listed Indivior (LSE: INDV) plunged 24.21% to 375.80 pence today, after it was revealed that the US Food and Drug Administration on Thursday approved the first generic versions of Indivior’s top-selling opioid addiction treatment Suboxone (buprenorphine and naloxone) sublingual film for the treatment of opioid dependence.
Netherlands-incorporated Mylan (Nasdaq: MYL) and India’s Dr Reddy's Laboratories (BSE: 500124) received approval to market buprenorphine and naloxone sublingual film in multiple strengths, and the latter has said it will be launching the drug, which will be on an ‘at risk’ basis due to ongoing litigation. Indivior had previously settled with Mylan until 2023; hence if Mylan also decides to launch behind Dr Reddy’s then it would also be at-risk.
Indivior will ‘pursue all legal remedies’
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze